Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders
Siddharth Srivastava, Jamie A. Love-Nichols, Kira A. Dies et al. · Genetics in Medicine · 2019
PURPOSE: For neurodevelopmental disorders (NDDs), etiological evaluation can be a diagnostic odyssey involving numerous genetic tests, underscoring the need to develop a streamlined algorithm maximizing molecular diagnostic yield for this clinical indication. Our objective was to compare the yield of exome sequencing (ES) with that of chromosomal microarray (CMA), the current first-tier test for NDDs. METHODS: We performed a PubMed scoping review and meta-analysis investigating the diagnostic yield of ES for NDDs as the basis of a consensus development conference. We defined NDD as global developmental delay, intellectual disability, and/or autism spectrum disorder. The consensus development conference included input from genetics professionals, pediatric neurologists, and developmental behavioral pediatricians. RESULTS: After applying strict inclusion/exclusion criteria, we identified 30 articles with data on molecular diagnostic yield in individuals with isolated NDD, or NDD plus associated conditions (such as Rett-like features). Yield of ES was 36% overall, 31% for isolated NDD, and 53% for the NDD plus associated conditions. ES yield for NDDs is markedly greater than previous studies of CMA (15-20%). CONCLUSION: Our review demonstrates that ES consistently outperforms CMA for evaluation of unexplained NDDs. We propose a diagnostic algorithm placing ES at the beginning of the evaluation of unexplained NDDs.
Cited by 689 works. doi:10.1038/s41436-019-0554-6
Authors
- Siddharth Srivastava
- Jamie A. Love-Nichols
- Kira A. Dies
- David H. Ledbetter
- Christa Lese Martin
- Wendy K. Chung
- Helen V. Firth
- Thomas William Frazier
- Robin L Hansen
- Lisa M. Prock
- Han G. Brunner
- Ny Hoang
- Stephen W. Scherer
- Mustafa Şahin
- David T. Miller
References
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
- Consensus methods: characteristics and guidelines for use.
- Consensus development methods, and their use in clinical guideline development.
- Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies
- Scoping reviews: time for clarity in definition, methods, and reporting
- Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics
- Clinical Exome Sequencing for Genetic Identification of Rare Mendelian Disorders
- Clinical application of whole-exome sequencing across clinical indications
- Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities
- Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders